Risk Factors Related to Acute Respiratory Distress Syndrome and Death in Patients with COVID-19: A Retrospective Cohort Study in Wuhan, China

Jing Wang
Huazhong University of Science and Technology Tongji Medical College

Lu Wang
Huazhong University of Science and Technology Tongji Medical College School of Public Health

Meng Jin
Wuhan University Renmin Hospital

Zequn Lu
Huazhong University of Science and Technology Tongji Medical College School of Public Health

Jun Xiao
Huazhong University of Science and Technology Tongji Medical College

Yao Li
Huazhong University of Science and Technology Tongji Medical College School of Public Health

Zhi Yao
Wuhan Pulmonary Hospital

Tianyi Dong
Huazhong University of Science and Technology Tongji Medical College School of Public Health

Yanan Wang
Huazhong University of Science and Technology Tongji Medical College

Siyou Niu
Huazhong University of Science and Technology Tongji Medical College School of Public Health

Qinglin Li
Wuhan Hankou Hospital

Cai Liu
Wuhan Hankou Hospital

Jirong Qi
Nanjing Children's Hospital Affiliated to Nanjing Medical University

Jianbo Tian
Huazhong University of Science and Technology Tongji Medical College School of Public Health

Zhihua Wang (✉ zwang_hust@hotmail.com)
Huazhong University of Science and Technology Tongji Medical College

---

Research article

Keywords: COVID-19, ARDS, prediction model

DOI: https://doi.org/10.21203/rs.3.rs-38911/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: The COVID-19 pandemic has been considered as the great threat to global public health. We aimed to clarify the risk factors associated with the development of acute respiratory distress syndrome (ARDS) and progression from ARDS to death and construct a risk prediction model.

Methods: In this single-centered, retrospective, and observational study, 796 COVID-19 patients developed ARDS and 735 COVID-19 patients without ARDS were matched by propensity score at an approximate ratio of 1:1 based on age, sex and comorbidities. Demographic data, symptoms, radiological findings, laboratory examinations, and clinical outcomes were compared between with or without ARDS. Univariable and multivariable logistic regression models were applied to explore the risk factors for development of ARDS and progression from ARDS to death and establish a comprehensive risk model.

Results: Higher SOFA, qSOFA, APACHE II and SIRS scores, elevated inflammatory cytokines, dysregulated multi-organ damage biomarkers, decreased immune cell subsets were associated with higher proportion of death (34.17% vs 1.22%; P<0.001) and increased risk odds of death (OR=57.216, 95%CI=28.373-115.378; P<0.001) in COVID-19 patients with ARDS. In addition to previous reported risk factors related to ARDS development and death, such as neutrophils, IL-6, D-Dimer, leukocytes and platelet, we identified elevated TNF-α (OR=1.146, 95%CI=1.100-1.194; P<0.001), CK-MB (OR=1.350, 95%CI=1.180-1.545; P<0.001), declined ALB (OR=0.834, 95%CI=0.799-0.872; P<0.001), CD8+ T cells (OR=0.983, 95%CI=0.976-0.990; P<0.001) and CD3-CD19+ B cells (OR=0.992, 95%CI=0.988-0.997; P=0.003) as novel risk factors. Most importantly, the predictive accuracy of the combined model integrating four score systems and these risk factors demonstrated highest among all models for the development of ARDS (AUC= 0.904) and the progression from ARDS to death (AUC= 0.959).

Conclusion: COVID-19 patients with ARDS were more likely to develop into death. The potential risk factors and the comprehensive prediction model could be helpful to identify patients developed ARDS with poor prognosis at an early stage, which might help physicians to formulate a timely therapeutic strategy.

Background

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has become a global pandemic. As of June 18, 2020, a total of 8,242,989 COVID-19 cases were confirmed globally with 445,535 deaths. Moreover, it is now clear that among hospitalized patients with COVID-19, pneumonia, sepsis, and respiratory failure are frequent complications, with some patients predisposed to poor clinical outcomes, while uncertainty regarding management of the complications arose in the course of this viral illness. To reasonably improve the prognosis of COVID-19 patients with complications, effective risk stratification and early intervention for patients are urgently needed.

The pathological study of biopsy specimens from COVID-19 patients has shown that the lung are the target organ for COVID-19 and the patients who develop acute lung injury are susceptible to acute respiratory distress syndrome (ARDS). Furthermore, ARDS is one of the most common critical complications and eventually might develop into severe systemic disease and multiple organ failure threatening the life safety of patients during deterioration of COVID-19. The sequential organ failure assessment (SOFA), quick SOFA (qSOFA), acute physiology and chronic health evaluation II (APACHE II) and systemic inflammatory response syndrome (SIRS) scores have been considered as good evaluation indexes for sepsis, septic shock, multi-organ dysfunction and even death in patients suffering from bacterial or viral pathogen infection. Notably, accumulative evidence has shown that SARS-CoV-2 caused inflammatory infiltration of interstitial mononuclear cells is related to disease progression from ARDS to death. Additionally, initial analyses of the patients with ARDS had shown that older age, high fever, neutrophilia, organ and coagulation dysfunction, and elevated D-Dimer levels were the risk factors associated with development of ARDS and death. However, due to the limitation of small sample size in previous studies, large researches are needed to fully describe the detailed biochemical biomarkers and risk factors related to adverse clinical outcomes of COVID-19 patients who develop ARDS. Most importantly, it is urgent to develop a comprehensive prediction model integrating these scores and risk factors associated with the progress of ARDS and death of patients with COVID-19, which is of great value for risk assessment, identification of disease-related biomarkers and provision of appropriate treatment.
In this single-centered, retrospective study, we performed a comprehensive analysis of the clinical features of patients with COVID-19 and ARDS admitted to Tongji Hospital, Wuhan. We provide a full clinical description of ARDS and non-ARDS patients, as well as survivors and non-survivors, and explore risk factors for ARDS and death in hospital patients. Finally, we aimed to construct a comprehensive risk prediction model by combining risk factors and scores, which is beneficial for early identification of development of ARDS and determination of effective treatments in COVID-19 patients.

Methods

Study Design and Participants

This is a single-center, retrospective cohort study of COVID-19 patients with confirmed SARS-COV-2 infection from Tongji Hospital, a designated hospital for severely or critically ill patients in Wuhan, China. A total of 3256 COVID-19 patients were diagnosed by WHO Interim guidance\(^{15}\) and admitted from January 13, 2020, to March 31, 2020. Among these patients, 796 COVID-19 patients with ARDS were enrolled and 735 COVID-19 patients without ARDS were statistically matched by propensity score based on age, sex and comorbidities with an approximate ratio of 1:1. The comorbidities included hypertension, diabetes, coronary heart disease, hepatitis, chronic obstructive pulmonary disease, chronic bronchitis and pulmonary tuberculosis. This research was approved by the Ethics Committee of Tongji Hospital Tongji Medical College, HUST, and waived informed consent of all participants.

Data Collection

The clinical retrospective data was retrieved through the electronic medical records of Tongji Hospital, including demographic characteristics, medical history, initial symptoms, laboratory findings, CT findings and treatment. The admission and hospitalized data of these patients were collected, reviewed and verified by a trained team of physicians. If the data was missing, uncertain or needed to be clarified, it would be collated and verified through communication with involved health-care providers or patients and their families.

Definitions

The ARDS patients was diagnosed based on the Berlin Definition.\(^{16}\) Throat swab samples were obtained to identify SARS-CoV-2 infection at admission and tested by real-time RT-PCR methods. The scores of SOFA, qSOFA, APACHE II and SIRS were calculated according to the physiological and laboratory parameters within 24 hours after admission. Details of these four scores and definitions of complication were presented in supplementary methods [see Additional file 1].

Statistical analysis

Continuous variables are expressed as median and interquartile range (IQR) or mean and standard deviation (SD), and categorical variables are expressed as numbers and percentages (%). For continuous variables, Student's t test was applied to normal distribution data, and Mann-Whitney U non-parameter test was applied to non-normal distribution data. Pearson's \(\chi^2\) test or Fisher's exact test was performed for categorical variables. Logistic regression models were used to estimate odds ratio (ORs) and 95% confidence intervals (95%CIs) to evaluate risk factors on the development and death risk of COVID-19 patients. The multivariate logistic model analysis was used to establish death risk prediction models. The significant variables from univariable analysis were considered as the candidates. Receiver operating characteristic (ROC) curves and area under the curve (AUC) was used to assess the predictive accuracy of each model. A two-sided \(P\) value < 0.05 was considered statistically significant. All statistical analyses were performed with SPSS (23.0), or R software (3.6.0).

Detailed methods can be seen in supplementary methods [see Additional file 1]

Results

Clinical characteristics and laboratory findings
796 (51.99%) COVID-19 patients with ARDS and 735 (48.01%) COVID-19 patients without ARDS were statistically matched by age, sex, and comorbidities in this study. The COVID-19 patients with ARDS were further classified into survivors (65.83%) and non-survivors (34.17%). Expectedly, COVID-19 patients with ARDS were more prevalent to be admitted to the intensive care unit (ICU) (19.24% vs 0.42%; \(P < 0.001\)) and had a higher proportion of death (34.17% vs 1.22%; \(P < 0.001\)) than those without ARDS (Table 1).
Table 1
Demographic, clinical, radiographic, laboratory findings of ARDS and non-ARDS patients with COVID-19

| Indicators                     | Total (N = 1531) | ARDS (N = 796) | Non-ARDS (N = 735) | P value |
|--------------------------------|------------------|----------------|--------------------|---------|
| **Characteristics**            |                  |                |                    |         |
| Age, years                     | 60.00 (51.00–68.00) | 61.00 (51.00–68.00) | 60.00 (50.00–68.00) | 0.091   |
| Sex                            |                  |                |                    |         |
| Male                           | 833 (54.41%)     | 445 (55.90%)   | 388 (52.79%)       | 0.221   |
| Female                         | 698 (45.59%)     | 351 (44.10%)   | 347 (47.21%)       |         |
| **Comorbidities**              |                  |                |                    |         |
| Hypertension                   | 454 (29.65%)     | 252 (31.66%)   | 202 (27.48%)       | 0.074   |
| Diabetes                       | 202 (13.19%)     | 108 (13.57%)   | 94 (12.79%)        | 0.653   |
| Coronary heart disease         | 99 (6.47%)       | 58 (7.29%)     | 41 (5.58%)         | 0.175   |
| Chronic obstructive pulmonary disease | 9 (0.59%) | 7 (0.88%)     | 2 (0.27%)          | 0.223   |
| Hepatitis                      | 28 (1.83%)       | 19 (2.39%)     | 9 (1.22%)          | 0.090   |
| Pulmonary tuberculosis         | 26 (1.70%)       | 16 (2.01%)     | 10 (1.36%)         | 0.326   |
| Chronic bronchitis             | 21 (1.37%)       | 12 (1.51%)     | 9 (1.22%)          | 0.634   |
| **Initial symptoms**           |                  |                |                    |         |
| Fever                          | 1036 (73.58%)    | 627 (84.73%)   | 409 (61.23%)       | < 0.001* |
| Cough                          | 943 (66.97%)     | 485 (65.54%)   | 458 (68.56%)       | 0.229   |
| Expectoration                  | 584 (41.48%)     | 273 (36.89%)   | 311 (46.56%)       | < 0.001* |
| Dyspnea                        | 560 (39.77%)     | 322 (43.51%)   | 238 (35.63%)       | 0.003*  |
| Fatigue                        | 234 (16.62%)     | 139 (18.78%)   | 95 (14.22%)        | 0.022*  |
| Chest tightness                | 217 (15.41%)     | 125 (16.89%)   | 92 (13.77%)        | 0.105   |
| Diarrhea                       | 308 (21.88%)     | 173 (23.38%)   | 135 (20.21%)       | 0.151   |
| Headache                       | 95 (6.75%)       | 57 (7.70%)     | 38 (5.69%)         | 0.132   |
| Myalgia                        | 126 (8.95%)      | 76 (10.27%)    | 50 (7.49%)         | 0.068   |
| Anorexia                       | 106 (7.53%)      | 60 (8.11%)     | 46 (6.89%)         | 0.386   |
| Vertigo                        | 52 (3.69%)       | 37 (5.00%)     | 15 (2.25%)         | 0.006*  |
| Chills                         | 148 (10.51%)     | 82 (11.08%)    | 66 (9.88%)         | 0.463   |
| **CT findings**                |                  |                |                    |         |
| Ground-glass opacity           | 621 (48.71%)     | 293 (50.78%)   | 328 (46.99%)       | 0.178   |
| Patchy shadows                 | 975 (76.47%)     | 449 (77.82%)   | 526 (75.36%)       | 0.303   |
| Fibrous stripes                | 471 (36.94%)     | 189 (32.76%)   | 282 (40.40%)       | 0.005*  |
| Pleural thickening             | 285 (22.35%)     | 158 (27.38%)   | 127 (18.19%)       | < 0.001* |
| Indicators          | Total         | ARDS          | Non-ARDS       | P value |
|--------------------|---------------|---------------|----------------|---------|
| Nodules            | 126(9.88%)    | 47(8.15%)     | 79(11.32%)     | 0.059   |
| Lymphadenia        | 263(20.63%)   | 132(22.88%)   | 131(18.77%)    | 0.071   |
| Bilateral pulmonary| 1204(94.43%)  | 555(96.19%)   | 649(92.98%)    | 0.013*  |
| Right lung         | 34(2.67%)     | 9(1.56%)      | 25(3.58%)      | 0.026*  |
| Left lung          | 35(2.75%)     | 12(2.08%)     | 23(3.30%)      | 0.186   |

**Laboratory examinations**

**Blood routine**

|                  | Total          | ARDS           | Non-ARDS        | P value |
|------------------|----------------|----------------|-----------------|---------|
| Leukocytes, # (N = 1531), × 10^9/L | 5.77(4.50–7.77) | 6.13(4.64–8.94) | 5.51(4.40–7.08) | < 0.001* |
| Erythrocytes, # (N = 1531), × 10^12/L | 4.22(3.81–4.62) | 4.22(3.74–4.62) | 4.21(3.84–4.62) | 0.294   |
| Neutrophils, # (N = 1531), × 10^9/L | 3.91(2.66–5.67) | 4.40(2.88–7.42) | 3.48(2.50–4.67) | < 0.001* |
| Eosinophils, # (N = 1531), × 10^9/L | 0.02(0.00–0.08) | 0.01(0.00–0.05) | 0.06(0.01–0.11) | < 0.001* |
| Basophils, # (N = 1531), × 10^9/L | 0.01(0.01–0.02) | 0.01(0.00–0.02) | 0.02(0.01–0.03) | < 0.001* |

**Immune cell subsets**

|                  | Total          | ARDS           | Non-ARDS        | P value |
|------------------|----------------|----------------|-----------------|---------|
| Lymphocytes, # (N = 1531), × 10^9/L | 1.11(0.73–1.57) | 0.88(0.60–1.28) | 1.35(0.98–1.79) | < 0.001* |
| CD3^+CD19^- T cells, # (N = 332), /µL | 1005.50(672.75–1304.00) | 845.00(362.50–1247.00) | 1073.00(849.00–1361.00) | < 0.001* |
| CD8^+ T cells, # (N = 332), /µL | 329.50(207.50–430.25) | 279.00(103.50–408.00) | 344.00(262.00–446.00) | < 0.001* |
| CD3^-CD19^+ B cells, # (N = 332), /µL | 176.50(115.50–251.25) | 152.00(76.00–238.00) | 184.00(135.00–261.00) | < 0.001* |
| CD3^-CD16^-CD56^- NK cells, # (N = 332), /µL | 160.50(100.00–260.50) | 138.00(55.00–235.00) | 192.00(125.00–282.00) | < 0.001* |
| T cells^+ B cells^+ NK cells, # (N = 332), /µL | 1401.50(956.75–1827.00) | 1194.00(646.50–1689.50) | 1545.00(1245.00–1874.00) | < 0.001* |

**Inflammatory cytokines and biomarkers**

|                  | Total          | ARDS           | Non-ARDS        | P value |
|------------------|----------------|----------------|-----------------|---------|
| IL-6 (N = 1260), pg/mL | 5.33(2.01–26.42) | 13.24(3.09–50.04) | 3.11(1.62–9.12) | < 0.001* |
| IL-10 (N = 1232), pg/mL | 5.00(5.00–6.80) | 5.00(5.00–9.85) | 5.00(5.00–5.00) | < 0.001* |
| IL-8 (N = 1233), pg/mL | 11.50(6.90–22.20) | 13.80(7.90–27.70) | 9.30(5.95–16.63) | < 0.001* |
| TNF-α (N = 1263), pg/mL | 5.70(5.80–10.40) | 8.30(6.13–11.40) | 7.30(5.30–9.50) | < 0.001* |
| IL-1β (N = 1232), pg/mL | 5.00(5.00–5.00) | 5.00(5.00–5.00) | 5.00(5.00–5.00) | 0.277   |
| IL-2R (N = 1226), U/mL | 529.00(345.00–844.00) | 658.00(410.50–1075.00) | 441.00(303.00–645.50) | < 0.001* |
| Indicators                      | Total            | ARDS             | Non-ARDS         | \( P \)  \\ value |
|--------------------------------|------------------|------------------|------------------|----------------------|
| **hs-CRP (N = 1497), mg/L**    | 20.70(2.50–72.00)| 47.80(10.10-105.80) | 5.20(1.20-33.35) | < 0.001*            |
| **Organ damage indexes**       |                  |                  |                  |                      |
| ALT (N = 1527), U/L            | 22.00(15.00–39.00) | 24.00(16.00–41.00) | 21.00(14.00–37.00) | 0.001*              |
| AST (N = 1527), U/L            | 26.00(19.00–39.00) | 31.00(21.00–48.00) | 23.00(18.00–31.00) | < 0.001*            |
| GGT (N = 1525), U/L            | 29.00(19.00–51.00) | 33.00(20.00–58.00) | 27.00(18.00–44.00) | < 0.001*            |
| ALB (N = 1524), g/L            | 36.00(32.08–40.40) | 34.30(30.20-37.88) | 38.60(34.43-42.00) | < 0.001*            |
| GLO (N = 1524), g/L            | 32.35(28.80–35.90) | 33.80(30.23–37.10) | 30.60(27.63-34.00) | < 0.001*            |
| TBIL (N = 1531), µmol/L        | 9.10(6.60–12.60)  | 9.80(7.00-13.80)  | 8.30(6.30–11.50)  | < 0.001*            |
| BUN (N = 1523), mmol/L         | 4.60(3.50–6.10)   | 4.90(3.40–7.40)   | 4.40(3.60-5.40)   | < 0.001*            |
| LDH (N = 1443), U/L            | 259.00(200.00-375.50) | 323.00(232.00-484.50) | 220.00(187.00-279.00) | < 0.001*             |
| eGFR (N = 1522), ml/(min*1.73m^2) | 92.90(79.03–103.40) | 91.95(72.98-103.73) | 94.15(83.73-103.08) | 0.002*               |
| Creatinine (N = 1531), µmol/L  | 70.00(58.00–86.00) | 72.50(57.00–92.00) | 70.00(59.00–81.00) | 0.009*              |
| NT-proBNP (N = 1240), pg/mL    | 106.00(35.00-365.25) | 186.50(60.00-816.50) | 62.00(25.00-156.25) | < 0.001*            |
| ALP (N = 1444), U/L            | 67.00(56.00–82.00) | 69.00(55.00–88.00) | 66.00(56.00–78.00) | 0.004*              |
| CK (N = 1012), U/L             | 68.00(43.75–118.00) | 74.00(43.00-153.00) | 63.00(44.00–94.00) | < 0.001*            |
| CK-MB (N = 1002), U/L          | 0.70(0.40–1.30)   | 0.80(0.40–2.10)   | 0.70(0.40–1.10)   | < 0.001*            |
| hs-cTnI (N = 1361), pg/mL      | 3.80(1.90–11.10)  | 5.70(2.40–20.00)  | 2.70(1.90–5.83)   | < 0.001*            |
| Platelet, # (N = 1531), ×10^9/L | 210.00(159.00-273.00) | 194.00(144.00-254.00) | 225.00(178.00-282.00) | < 0.001*             |
| TT (N = 654), s                | 16.70(15.80–17.70) | 16.75(15.70-18.10) | 16.50(15.90–17.30) | 0.040*              |
| PT (N = 1513), s               | 13.80(13.20–14.50) | 14.00(13.40–15.10) | 13.60(13.20–14.10) | < 0.001*            |
| APTT (N = 1432), s             | 38.90(35.90–42.70) | 39.30(36.00-43.70) | 38.30(35.80-41.70) | 0.001*              |
| D-Dimer (N = 1497), ug/mL      | 0.64(0.32–1.77)   | 1.12(0.48–2.89)   | 0.43(0.22–0.88)   | < 0.001*            |
| FDP (N = 1104), g/L            | 4.00(4.00-7.30)   | 5.20(4.00-18.05)  | 4.00(4.00–4.00)   | < 0.001*            |
| Indicators                   | Total                          | ARDS                           | Non-ARDS                       | P value |
|-----------------------------|-------------------------------|--------------------------------|--------------------------------|---------|
| **Score prediction**        |                               |                                |                                |         |
| SOFA score                  | 3.00(3.00–4.00)               | 3.00(2.00–5.00)                | 2(1.00–2.00)                   | < 0.001*|
| qSOFA score                 | 0.00(0.00–1.00)               | 1.00(0.00–1.00)                | 0(0.00–0.00)                   | < 0.001*|
| APACHE II score             | 10.00(6.00-15.50)             | 13.00(8.00-17.50)              | 7.00(4.00–10.00)               | < 0.001*|
| SIRS score                  | 1.00(0.00–2.00)               | 2.00(1.00–2.00)                | 1.00(0.00–2.00)                | < 0.001*|
| **ICU admission**           | N = 1503                      | N = 785                        | N = 718                        |         |
| ICU                         | 154(10.25%)                   | 151(19.24%)                    | 3(0.42%)                       | < 0.001*|
| Non-ICU                     | 1349(89.75%)                  | 634(80.76%)                    | 715(99.58%)                    |         |
| **Outcomes**                | N = 1531                      | N = 796                        | N = 735                        |         |
| Survivor                    | 1250(81.65%)                  | 524(65.83%)                    | 726(98.78%)                    | < 0.001*|
| Non-survivor                | 281(18.35%)                   | 272(34.17%)                    | 9(1.22%)                       |         |

Abbreviation: COVID-19, Corona virus disease 2019; CT, Computerized tomography; CD, Cluster of differentiation; NK cells, Natural killer cells; IL-6, Interleukin 6; IL-10, Interleukin 10; IL-8, Interleukin 8; TNF-α, Tumor necrosis factor α; IL-1β, Interleukin 1β; IL-2R, Interleukin 2 receptor; hs-CRP, High-sensitivity C-reactive protein; ALT, Glutamic-pyruvic transaminase; AST, Glutamic-oxaloacetic transaminase; GGT, Gamma-glutamyl transpeptidase; ALB, Albumin; GLO, Globulin; TBIL, Total bilirubin; BUN, Blood urea nitrogen; LDH, Lactic dehydrogenase; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal of the prohormone brain natriuretic peptide; ALP, Alkaline phosphatase; CK, Creatine kinase; CK-MB, Creatine kinase-MB; hs-cTnl, Hypersensitive cardiac troponin I; TT, Thrombin time; PT, Prothrombin time; APTT, Activated partial thromboplastin time; FDP, Fibrinogen degradation products; SOFA, Sequential organ failure assessment; qSOFA, quick SOFA; APACHE II, The acute physiology and chronic health evaluation II; SIRS, The systemic inflammatory response syndrome; ECMO, extracorporeal membrane oxygenation; IQR, Interquartile range; SD, standard deviation. Continuous variables were described as median (IQR) or mean and standard deviation (SD). P values were calculated by Mann-Whitney U non-parameter test for skewed distributed data or Student's t-test for normal distributed data (b). Categorical variables were expressed as number (%). P values were calculated by Pearson χ² test. *P < 0.05.

As shown in Table 1, symptoms such as fever (84.73% vs 61.23%; P<0.001), dyspnea (43.51% vs 35.63%; P=0.003), fatigue(18.78% vs 14.22%; P=0.022), and vertigo (5.00% vs 2.25%; P=0.006) were more prevalent in COVID-19 patients with ARDS. Fever (89.52% vs 82.32%; P=0.010), dyspnea (50.00% vs 40.20%; P=0.012) and vertigo (7.30% vs 3.90%; P=0.045) were more pronounced in non-survivors (Table2). Moreover, patchy shadows and bilateral pulmonary involvement were found in majority of COVID-19 patients, while the difference of patchy shadows was not statistically significant between patients with and without ARDS (Table 1).
Table 2. Demographic, clinical, radiographic, laboratory findings of non-survivors and survivors COVID-19 patients with ARDS

| Indicators                              | Total N = 796 | non-survivors N = 272 | survivors N = 524 | P value |
|-----------------------------------------|---------------|------------------------|-------------------|---------|
| Characteristics                         |               |                        |                   |         |
| Age, years                              |               |                        |                   | <0.001* |
| Male                                    |               |                        |                   | <0.001* |
| Female                                  |               |                        |                   |         |
| Comorbidities                           |               |                        |                   |         |
| Hypertension                            |               |                        |                   | 0.001*  |
| Diabetes                                |               |                        |                   | 0.811   |
| Coronary heart disease                  |               |                        |                   | <0.001* |
| Chronic obstructive pulmonary disease   |               |                        |                   | 0.375   |
| Hepatitis                               |               |                        |                   | 0.804   |
| Pulmonary tuberculosis                  |               |                        |                   | 0.060   |
| Chronic bronchitis                      |               |                        |                   | 0.037*  |
| Initial symptoms                        |               |                        |                   |         |
| Fever                                   |               |                        |                   | 0.010*  |
| Cough                                   |               |                        |                   | 0.364   |
| Expectoration                           |               |                        |                   | 0.063   |
| Dyspnea                                 |               |                        |                   | 0.012*  |
| Fatigue                                 |               |                        |                   | 0.630   |
| Chest tightness                         |               |                        |                   | 0.694   |
| Diarrhea                                |               |                        |                   | 0.851   |
| Headache                                |               |                        |                   | 0.018*  |
| Myalgia                                 |               |                        |                   | 0.003*  |
| Anorexia                                |               |                        |                   | 0.799   |
| Vertigo                                 |               |                        |                   | 0.045*  |
| Chills                                  |               |                        |                   | 0.266   |
| CT findings                             |               |                        |                   |         |
| Ground-glass opacity                    |               |                        |                   | 0.566   |
| Patchy shadows                          |               |                        |                   | 0.260   |
| Fibrous stripes                         |               |                        |                   | 0.004*  |
| Pleural thickening                      |               |                        |                   | 0.009*  |
| Nodules                                 |               |                        |                   | 1.000   |
| Lymphadenia                             |               |                        |                   | 0.003*  |
| Bilateral pulmonary                     |               |                        |                   | 0.223   |
|                      | Right lung |             |             | Left lung |             |             |
|----------------------|------------|-------------|-------------|-----------|-------------|-------------|
|                      | 9(1.60%)   | 0(0.00%)    | 9(1.70%)    | 12(2.10%) | 0(0.00%)    | 12(2.30%)   |
|                      |            |             |             |           |             |             |
|                      | 0.610a     |             |             | 0.503     |             |             |

**Laboratory examinations**

**Blood routine**

|                      |            |             |             |            |             |             |
|----------------------|------------|-------------|-------------|-----------|-------------|-------------|
| Leukocytes, # (N = 796), \*10^9/L | 6.13(4.63-8.95) | N = 272 | 9.06(6.01-13.10) | N = 524 | 5.37(4.27-7.09) | <0.001* |
| Erythrocytes, # (N = 796), \*10^12/L | 4.22(3.74-4.62) | N = 272 | 4.17(3.58-4.63) | N = 524 | 4.25(3.83-4.62) | 0.013* |
| Neutrophils, # (N = 796), \*10^9/L | 4.40(2.88-7.42) | N = 272 | 7.87(4.51-11.83) | N = 524 | 3.77(2.64-5.28) | <0.001* |
| Eosinophils, # (N = 796), \*10^9/L | 0.01(0.00-0.05) | N = 272 | 0.00(0.00-0.01) | N = 524 | 0.02(0.00-0.07) | <0.001* |
| Basophils, # (N = 796), \*10^9/L | 0.01(0.00-0.02) | N = 272 | 0.01(0.00-0.02) | N = 524 | 0.01(0.00-0.02) | 0.727 |

**Immune cell subsets**

|                      |            |             |             |            |             |             |
|----------------------|------------|-------------|-------------|-----------|-------------|-------------|
| Lymphocytes, # (N = 796), \*10^9/L | 0.88(0.60-1.28) | N = 272 | 0.63(0.43-0.85) | N = 524 | 1.07(0.74-1.45) | <0.001* |
| CD3^+CD19^− T cells, # (N = 159), /μL | 845.00(359.00-1252.00) | N = 53 | 279.00(135.50-417.50) | N = 106 | 1082.00(800.00-1405.25) | <0.001* |
| CD8^+ T cells, # (N = 159), /μL | 279.00(103.00-408.00) | N = 53 | 63.00(29.50-130.50) | N = 106 | 365.00(267.25-494.75) | <0.001* |
| CD3^+CD19^− B cells, # (N = 159), /μL | 152.00(75.00-239.00) | N = 53 | 75.00(40.00-148.50) | N = 106 | 183.00(124.00-274.50) | <0.001* |
| CD3^+CD16^+CD56^+ NK cells, # (N = 159), /μL | 138.00(55.00-238.00) | N = 53 | 35.00(15.50-76.50) | N = 106 | 181.00(125.00-288.50) | <0.001* |
| T cells^+ B cells^+ NK cells, # (N = 159), /μL | 1194.00(634.00-1709.00) | N = 53 | 424.00(272.50-703.00) | N = 106 | 1466.50(1189.50-1922.25) | <0.001* |

**Inflammatory cytokines and biomarkers**

|                      |            |             |             |            |             |             |
|----------------------|------------|-------------|-------------|-----------|-------------|-------------|
| IL-6 (N = 646), pg/mL | 13.24(3.08-50.05) | N = 195 | 61.60(29.22-153.10) | N = 451 | 5.20(2.08-21.12) | <0.001* |
| IL-10 (N = 632), pg/mL | 5.00(5.00-9.95) | N = 191 | 10.30(6.30-18.70) | N = 441 | 5.00(5.00-6.20) | <0.001* |
| IL-8 (N = 633), pg/mL | 13.80(7.90-27.85) | N = 192 | 28.75(16.48-62.88) | N = 441 | 10.40(6.65-18.40) | <0.001* |
| TNF-α (N = 642), pg/mL | 8.30(6.10-11.40) | N = 192 | 11.55(8.23-17.25) | N = 450 | 7.55(5.60-9.80) | <0.001* |
| IL-1β (N = 632), pg/mL | 5.00(5.00-5.00) | N = 192 | 5.00(5.00-7.08) | N = 440 | 5.00(5.00-5.00) | <0.001* |
| IL-2R (N = 631), U/mL | 658.00(409.00-1077.00) | N = 190 | 1148.00(726.75-1634.00) | N = 441 | 538.00(358.00-813.00) | <0.001* |
| hs-CRP (N = 789), mg/L | 47.80(10.10-106.15) | N = 267 | 105.80(59.60-164.40) | N = 522 | 23.75(3.90-68.65) | <0.001* |

**Organ damage indexes**

|                      |            |             |             |            |             |             |
|----------------------|------------|-------------|-------------|-----------|-------------|-------------|
| ALT (N = 796), U/L | 24.00(16.00-41.00) | N = 272 | 27.00(18.00-42.00) | N = 524 | 23.00(15.00-40.00) | 0.013* |
| AST (N = 796), U/L | 31.00(21.00-72.50) | N = 272 | 41.00(28.25-51.50) | N = 524 | 26.00(19.00-38.00) | <0.001* |
| Test | Unit | Control | N = 795 | N = 794 | N = 796 | N = 770 | N = 533 | N = 471 | N = 713 | N = 796 | N = 233 | N = 233 | N = 233 | N = 233 |
|------|------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| GGT  | U/L  | 33.00(20.00-58.00) | N = 272 | 39.00(24.25-70.00) | N = 523 | 30.00(19.00-52.00) | <0.001* |
| ALB  | g/L  | 34.24±5.59 | N = 271 | 30.76±4.79 | N = 523 | 36.04±5.10 | <0.001* |
| GLO  | g/L  | 33.80(30.20-37.13) | N = 271 | 35.70(31.50-39.20) | N = 523 | 32.90(29.80-36.00) | <0.001* |
| TBIL | μmol/L | 9.80(7.00-13.80) | N = 272 | 12.40(9.03-18.80) | N = 524 | 8.70(6.40-11.70) | <0.001* |
| BUN  | mmol/L | 4.90(3.40-7.43) | N = 270 | 8.30(5.60-13.08) | N = 524 | 4.05(3.10-5.40) | <0.001* |
| LDH  | U/L  | 323.00(232.00-485.00) | N = 268 | 504.50(366.00-670.50) | N = 499 | 268.00(206.00-366.00) | <0.001* |
| eGFR | ml/(min*1.73m^2) | 91.95(72.93-103.78) | N = 269 | 72.70(47.95-90.95) | N = 523 | 97.00(86.00-106.50) | <0.001* |
| Creatinine | μmol/L | 72.50(57.00-92.00) | N = 272 | 87.00(67.00-114.00) | N = 524 | 66.00(55.00-83.00) | <0.001* |
| NT-proBNP | pg/mL | 186.50(60.00-819.50) | N = 244 | 888.50(367.25-2602.50) | N = 412 | 86.50(34.25-219.50) | <0.001* |
| ALP  | U/L  | 69.00(55.00-88.25) | N = 272 | 78.50(62.00-109.00) | N = 498 | 65.00(54.00-80.00) | <0.001* |
| CK   | U/L  | 74.00(43.00-154.00) | N = 187 | 128.00(69.00-335.00) | N = 346 | 61.00(37.00-106.25) | <0.001* |
| CK-MB | U/L | 0.80(0.40-2.10) | N = 168 | 2.45(1.20-5.95) | N = 303 | 0.60(0.30-0.90) | <0.001* |
| hs-cTnI | pg/mL | 5.70(2.40-20.15) | N = 252 | 35.90(11.20-201.98) | N = 461 | 3.30(1.90-6.40) | <0.001* |
| Platelet, # | ×10^9/L | 194.00(144.00-254.00) | N = 272 | 159.00(107.25-222.75) | N = 524 | 207.50(160.00-276.50) | <0.001* |
| TT   | s    | 16.75(15.70-18.13) | N = 239 | 17.00(15.80-19.20) | N = 159 | 16.40(15.60-17.20) | <0.001* |
| PT   | s    | 14.00(13.40-15.10) | N = 272 | 15.35(14.30-17.10) | N = 519 | 13.70(13.10-14.30) | <0.001* |
| APTT | s    | 39.30(36.00-43.70) | N = 241 | 40.10(36.10-46.20) | N = 492 | 39.10(36.00-42.80) | 0.006* |
| D-Dimer | ug/mL | 1.12(0.48-2.89) | N = 266 | 4.29(1.48-16.20) | N = 515 | 0.64(0.37-1.40) | <0.001* |
| FDP  | g/L  | 5.20(4.00-18.15) | N = 206 | 26.10(7.40-89.25) | N = 358 | 4.00(4.00-5.83) | <0.001* |

**Score prediction**

| Score | N = 233 | N = 233 | N = 233 | N = 233 | N = 233 | N = 233 | N = 233 | N = 233 | N = 233 | N = 233 | N = 233 | N = 233 | N = 233 | N = 233 |
|-------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| SOFA score | 3.00(2.00-5.00) | N = 118 | 4.00(3.00-6.00) | N = 115 | 2.00(2.00-3.00) | <0.001* |
| qSOFA score | 1.00(0.00-1.00) | N = 118 | 1.00(1.00-1.00) | N = 115 | 0.00(0.00-1.00) | <0.001* |
| APACHE II score | 13.00(8.00-17.50) | N = 118 | 17.00(14.00-20.25) | N = 115 | 8.00(5.00-11.00) | <0.001* |
| SIRS score | 2.00(1.00-2.00) | N = 118 | 2.00(1.00-2.00) | N = 115 | 1.00(0.00-2.00) | <0.001* |

**ICU**

|      | N = 785 | N = 272 | N = 513 |
|------|---------|---------|---------|
|      |         |         |         |
We observed that the levels of inflammatory cytokines were substantially elevated in patients with ARDS, including IL-6 (13.24 vs 3.11 pg/mL; P<0.001), h(47.80 vs 5.20 pg/mL; P<0.001), TNF-α (8.30 vs 7.30 pg/mL; P<0.001). Conversely, the counts of immune cell subsets, including CD3⁺CD19¹ T cells (845.00 vs 1073.00 /μL; P<0.001), CD8⁺ T cells (279.00 vs 344.00 /μL; P<0.001), NK cells (138.00 vs 209.00 /μL; P<0.001) as well as the total number of T cells, B cells and NK cells (406.00 vs 192.00 /μL; P<0.001), were significantly decreased in the patients with ARDS (Table 1).

We also observed dysregulated cardiac injury biomarkers, liver damage indexes and coagulation biomarkers were more pronounced in patients with ARDS. Our study showed that significantly increased CK-MB (0.80 vs 0.70 U/L; P<0.001), creatinine (72.50 vs 70.00 μmol/L; P=0.009), D-Dimer (1.12 vs 0.43 μg/mL; P<0.001) and FDP (5.20 vs 4.00 g/L; P=0.002) presented in ARDS group (Table 1). Compared with survivors, the same results can be found in non-survivors (Table 2). Other laboratory indexes in patients with and without ARDS, as well as non-survivors and survivors, were presented in the Supplementary Table 1 [see Additional file 2] and Supplementary Table 2 [see Additional file 3]. These findings indicated that aggravated inflammatory responses, lymphopenia, and multiple-organ damage might be correlated with the development of ARDS and subsequently worse clinical outcomes.

Comorbidities, Complications, And Clinical Treatments

Consistent with previous studies, COVID-19 patients with ARDS had an increased risk of developing other serious complications, more patients with ARDS presented with acute liver injury (9.92% vs 1.36%; P<0.001), acute kidney injury (18.22% vs 2.31%; P<0.001), heart failure (27.89% vs 2.31%; P<0.001), cardiac injury (20.40% vs 5.71%; P<0.001), and disseminated intravascular coagulation (DIC), 6.91% vs 0.27%; P<0.001) (Table 1). The similar results were found in the comparison of non-survivors and survivors in COVID-19 patients with ARDS (Table 2).

In terms of clinical treatments, more patients with ARDS frequently received antibiotic treatment (85.55% vs 65.31%), antiviral therapy (54.52% vs 42.59%), glucocorticoid therapy (63.44% vs 23.95%), and intravenous immunoglobulin therapy (41.33% vs 18.78%; P<0.001). Remarkably, patients with ARDS required more clinical oxygen support, including high-flow oxygen ventilation (55.53% vs 41.50%; P<0.001) and mechanical ventilation (23.87% vs 2.04%; P<0.001). Besides, except for antiviral therapy and high-flow oxygen therapy, all forms of clinical treatments were given more in non-survivors (Table 2).

Risk Factors

Multivariate Logistic models were calculated to explore risk factors for development of ARDS and death among COVID-19 patients with adjustment of age, sex, and comorbidities. (Table 3). We observed that elevated inflammatory cytokines were substantially associated with the higher risk for disease progression of ARDS and death in COVID-19 patients, such as IL-6 (OR = 1.021, 95%CI = 1.016–1.026; P<0.001), TNF-α (OR = 1.146, 95%CI = 1.100–1.194; P<0.001), IL-10 (OR = 1.126, 95%CI = 1.087–1.166; P<0.001), and

| Abbreviation: COVID-19, Corona virus disease 2019; CT, Computerized tomography; CD, Cluster of differentiation; NK cells, Natural killer cells; IL-6, Interleukin 6; IL-10, Interleukin 10; IL-8, Interleukin 8; TNF-α, Tumor necrosis factor α; IL-1β, Interleukin 1β; IL-2R, Interleukin 2 receptor; hs-CRP, High-sensitivity C-reactive protein; ALT, Glutamic-pyruvic transaminase; AST, Glutamic-oxaloacetic transaminase; GGT, Gamma-glutamyl transpeptidase; ALB, Albumin; GLO, Globulin; TBIL, Total bilirubin; BUN, Blood urea nitrogen; LDH, Lactic dehydrogenase; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal of the prohormone brain natriuretic peptide; ALP, Alkaline phosphatase; CK, Creatine kinase; CK-MB, Creatine kinase-MB; hs-cTnI, Hypersensitive cardiac troponin I; TT, Thrombin time; PT, Prothrombin time; APTT, activated partial thromboplastin time; FDP, Fibrinogen degradation products; SOFA, Sequential organ failure assessment; qSOFA, quick SOFA; APACHE II, The acute physiology and chronic health evaluation II; SIRS, The systemic inflammatory response syndrome; ECMO, extracorporeal membrane oxygenation; IQR, Interquartile range; SD, standard deviation. Continuous variables were described as median (IQR) or mean and standard deviation (SD). P-values were calculated by Mann-Whitney U non-parameter test for skewed distributed data or Student's t-test for normal distributed data (b). Categorical variables were expressed as number (%). Pvalues were calculated by Pearson χ² test or Fisher's exact test (a). *P< 0.05.
hs-CRP (OR = 1.016, 95%CI = 1.013–1.019; P < 0.001). Conversely, the decreased level of counts of immune cell subsets, such as lymphocytes (OR = 0.365, 95%CI = 0.244–0.545; P < 0.001), CD8+ T cells (OR = 0.983, 95%CI = 0.976–0.990; P < 0.001), CD3–CD19+ B cells (OR = 0.992, 95%CI = 0.988–0.997; P = 0.003) were significantly related to the lower risk of the progression from ARDS to death. Additionally, we found that multiple-organ damage biomarkers, including decreased ALB (OR = 0.834, 95%CI = 0.799–0.872; P < 0.001), elevated AST (OR = 1.004, 95%CI = 1.001–1.007; P = 0.017), CK-MB (OR = 1.350, 95%CI = 1.180–1.545; P < 0.001), creatinine (OR = 1.007, 95%CI = 1.003–1.012; P < 0.002), D-Dimer (OR = 1.272, 95%CI = 1.207–1.340; P < 0.001) and FDP (OR = 1.052, 95%CI = 1.038–1.066; P < 0.001), might associate with high risk of progression of ARDS and outcome of COVID-19 patients.
Table 3
Risk Factors Associated with ARDS Development or Progression from ARDS to Death

| Indicators                      | ARDS                          | Death                        |
|---------------------------------|-------------------------------|------------------------------|
|                                 | Univariable logistic regression | Multivariable logistic regression | Univariable logistic regression | Multivariable logistic regression |
|                                 | OR (95% CI)                   | P value                      | OR (95% CI)                   | P value                      |
| Leukocytes, #, × 10⁹/L          | 1.154(1.113–1.196)            | < 0.001*                     | 1.148(1.107–1.190)            | < 0.001*                     |
| Erythrocytes, #, × 10¹²/L       | 0.862(0.741–1.002)            | 0.053                        | 0.850(0.719–1.005)            | 0.057                        |
| Monocytes, #, × 10⁹/L           | 1.012(0.930–1.100)            | 0.786                        | 1.017(0.936–1.104)            | 0.696                        |
| Neutrophils, #, × 10⁹/L         | 1.250(1.198–1.305)            | < 0.001*                     | 1.249(1.195–1.305)            | < 0.001*                     |
| Eosinophils, #, × 10⁹/L         | 0.001(0.000–0.007)            | < 0.001*                     | 0.002(0.000–0.007)            | < 0.001*                     |
| Lymphocytes, #, × 10⁹/L         | 0.333(0.275–0.402)            | < 0.001*                     | 0.326(0.267–0.398)            | < 0.001*                     |
| CD3⁺CD19⁻ T cells, #, /µL       | 0.999(0.998–0.999)            | < 0.001*                     | 0.999(0.998–0.999)            | < 0.001*                     |
| CD3⁺CD8⁺ T cells, # (N=332, /µL)| 0.998(0.996–0.999)            | < 0.001*                     | 0.998(0.996–0.999)            | 0.001*                       |
| CD3⁻CD19⁺ B cells, #, /µL       | 0.998(0.996–0.999)            | 0.012*                       | 0.998(0.996–1.000)            | 0.045*                       |
| CD3⁻CD16⁺CD56⁺ NK cells, #, /µL | 0.996(0.994–0.998)            | < 0.001*                     | 0.996(0.994–0.998)            | < 0.001*                     |
| T cells⁺ B cells⁺ NK cells, #, /µL | 0.999(0.999–0.999)            | < 0.001*                     | 0.999(0.998–0.999)            | < 0.001*                     |
| IL-6, pg/mL                     | 1.020(1.015–1.025)            | < 0.001*                     | 1.021(1.016–1.026)            | < 0.001*                     |
| IL-10, pg/mL                    | 1.073(1.045–1.101)            | < 0.001*                     | 1.070(1.043–1.098)            | < 0.001*                     |
| IL-8, pg/mL                     | 1.000(1.000–1.000)            | 0.958                        | 1.000(1.000–1.000)            | 0.946                        |
| TNF-α, pg/mL                    | 1.076(1.050–1.102)            | < 0.001*                     | 1.075(1.048–1.102)            | < 0.001*                     |
| IL-1β, pg/mL                    | 0.996(0.983–1.009)            | 0.556                        | 0.995(0.982–1.009)            | 0.498                        |
| IL-2R, U/mL                     | 1.002(1.001–1.002)            | < 0.001*                     | 1.002(1.001–1.002)            | < 0.001*                     |
### Indicators

| Indicators | ARDS | Death |
|------------|------|-------|
|            | Univariable logistic regression | Multivariable logistic regression | Univariable logistic regression | Multivariable logistic regression |
|            | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value |
| hs-CRP, mg/L | 1.016 (1.013–1.019) | < 0.001* | 1.017 (1.014–1.020) | < 0.001* | 1.018 (1.015–1.021) | < 0.001* | 1.016 (1.013–1.019) | < 0.001* |
| ALT, U/L | 1.004 (1.002–1.007) | 0.002* | 1.004 (1.002–1.007) | 0.003* | 1.002 (1.000–1.003) | 0.113 | 1.001 (0.999–1.004) | 0.283 |
| AST, U/L | 1.021 (1.016–1.027) | < 0.001* | 1.021 (1.015–1.027) | < 0.001* | 1.006 (1.003–1.010) | 0.001* | 1.004 (1.001–1.007) | 0.017* |
| GGT, U/L | 1.004 (1.002–1.006) | < 0.001* | 1.004 (1.002–1.006) | < 0.001* | 1.002 (1.000–1.004) | 0.031* | 1.002 (1.000–1.004) | 0.064 |
| ALB, g/L | 0.871 (0.853–0.890) | < 0.001* | 0.858 (0.838–0.878) | < 0.001* | 0.803 (0.772–0.834) | < 0.001* | 0.834 (0.799–0.872) | < 0.001* |
| GLO, g/L | 1.095 (1.073–1.117) | < 0.001* | 1.094 (1.072–1.117) | < 0.001* | 1.074 (1.045–1.103) | < 0.001* | 1.043 (1.010–1.076) | 0.009* |
| BUN, mmol/L | 1.149 (1.107–1.192) | < 0.001* | 1.160 (1.112–1.209) | < 0.001* | 1.535 (1.429–1.650) | < 0.001* | 1.369 (1.268–1.478) | < 0.001* |
| LDH, U/L | 1.008 (1.007–1.009) | < 0.001* | 1.008 (1.007–1.009) | < 0.001* | 1.008 (1.007–1.009) | < 0.001* | 1.007 (1.006–1.009) | < 0.001* |
| eGFR, ml/ (min*1.73m^2 | 0.989 (0.984–0.993) | < 0.001* | 0.989 (0.983–0.994) | < 0.001* | 0.958 (0.951–0.965) | < 0.001* | 0.974 (0.966–0.982) | < 0.001* |
| Creatinine, μmol/L | 1.003 (1.001–1.006) | 0.007* | 1.003 (1.000–1.005) | 0.024* | 1.018 (1.013–1.024) | < 0.001* | 1.007 (1.003–1.012) | 0.002* |
| NT-proBNP, pg/mL | 1.001 (1.001–1.001) | < 0.001* | 1.001 (1.001–1.002) | < 0.001* | 1.001 (1.000–1.001) | < 0.001* | 1.000 (1.000–1.000) | < 0.001* |
| CK, U/L | 1.004 (1.002–1.005) | < 0.001* | 1.003 (1.002–1.005) | < 0.001* | 1.003 (1.002–1.004) | < 0.001* | 1.003 (1.002–1.005) | < 0.001* |
| CK-MB, U/L | 1.228 (1.129–1.337) | < 0.001* | 1.205 (1.106–1.314) | < 0.001* | 1.714 (1.472–1.997) | < 0.001* | 1.350 (1.180–1.545) | < 0.001* |
| hs-cTnI, pg/mL | 1.010 (1.006–1.015) | < 0.001* | 1.010 (1.006–1.014) | < 0.001* | 1.001 (1.000–1.001) | 0.002* | 1.000 (1.000–1.001) | 0.029* |
| Platelet, #, × 10^9/L | 0.997 (0.995–0.998) | < 0.001* | 0.997 (0.996–0.998) | < 0.001* | 0.993 (0.991–0.995) | < 0.001* | 0.995 (0.992–0.997) | < 0.001* |
| PT, s | 1.536 (1.396–1.691) | < 0.001* | 1.545 (1.396–1.710) | < 0.001* | 2.359 (2.033–2.738) | < 0.001* | 2.118 (1.800–2.492) | < 0.001* |
| APTT, s | 1.036 (1.019–1.054) | < 0.001* | 1.035 (1.017–1.054) | 0.00012* | 1.055 (1.032–1.080) | < 0.001* | 1.057 (1.028–1.087) | < 0.001* |
| D-Dimer, ug/mL | 1.415 (1.303–1.536) | < 0.001* | 1.438 (1.318–1.568) | < 0.001* | 1.305 (1.237–1.377) | < 0.001* | 1.272 (1.207–1.340) | < 0.001* |
| FDP, g/L | 1.053 (1.037–1.070) | < 0.001* | 1.055 (1.038–1.072) | < 0.001* | 1.063 (1.047–1.079) | < 0.001* | 1.052 (1.038–1.066) | < 0.001* |

### Score prediction

| Score prediction | ARDS | Death |
|------------------|------|-------|
| SOFA score | 3.598 (2.696–4.802) | < 0.001* | 4.035 (2.917–5.581) | < 0.001* | 3.342 (2.413–4.630) | < 0.001* | 3.087 (2.137–4.460) | < 0.001* |
## Comprehensive prediction models

All four predictive score systems, including SOFA, qSOFA, APACHE II and SIRS, performed good prediction capacities for assessing the development risk of ARDS among COVID-19 patients and death risk among patients who developed ARDS. AUCs (95% CI) of SOFA, qSOFA, APACHE II and SIRS scores in assessing the progression of ARDS in COVID-19 patients were 0.857 (0.820–0.894), 0.701 (0.659–0.744), 0.729 (0.679–0.780) and 0.672 (0.618–0.725). Furthermore, all of them had prominent prediction capacities evaluating death risk. AUCs (95% CI) of SOFA, qSOFA, APACHE II and SIRS scores were 0.853 (0.807–0.900), 0.743 (0.686–0.799), 0.907 (0.870–0.944) and 0.693 (0.627–0.758) (Fig. 1).

Furthermore, based on inflammatory-related indexes, multiple-organ damage biomarkers and immune cell subsets, we constructed another three prediction models, all of which were significantly associated with the ARDS development and death. Discrimination of ARDS development risk models was better using multiple-organ damage biomarkers (AUC = 0.779, 95% CI = 0.746–0.812). The AUCs of inflammatory-related indexes model and immune cell subsets model were 0.729 (0.701–0.757) and 0.687 (0.629–0.746). Conversely, the highest predictive capacities of three prediction models of death was the immune cell subsets group model (AUC = 0.954, 95% CI = 0.924–0.985). AUCs of multiple-organ damage biomarkers model and inflammatory-related indexes model were 0.927 (0.901–0.952), and 0.899 (0.874–0.924) (Fig. 1).

Overall, we established a combined group by integrating four predictive scores, inflammatory-related indexes, immune cell subsets and multiple-organ damage biomarkers. The accuracy of combined score for predicting ARDS development was 0.904 (0.866–0.942), and that for the death was 0.959 (0.931–0.986). The predictive accuracy of the combined model demonstrated highest among all models in development of ARDS and progression from ARDS to death, indicating that the combined score system of great value in the evaluation of the development and death risk of ARDS in patients with COVID-19 (Fig. 1).

## Discussion

In this retrospective cohort study, we found that COVID-19 patients with ARDS were more likely to develop into death. Moreover, patients with elevated inflammatory-related indexes, decreased immune cell subsets, abnormal multiple-organ damage biomarkers and higher scores were more likely to develop ARDS and progress from ARDS to death. Specifically, in addition to previously reported risk factors such as neutrophils, IL-6, D-Dimer, leukocytes and platelet, we identified novel risk factors including elevated TNF-α, ALB...
and CK-MB as well as decreased CD8$^{+}$ T cell and CD3$^{-}$CD19$^{+}$ B cells. Furthermore, we established a comprehensive risk prediction model by combining risk factors and scores which showed good prediction accuracy for ARDS development (AUC = 0.904) and ARDS death risk (AUC = 0.959). This model will be beneficial for early identification of development of ARDS and determination of effective treatments in COVID-19 patients.

Enrolled 796 COVID-19 patients with ARDS were statistically matched by age, sex, and comorbidities to those without ARDS. We noted that patients with ARDS presented excessive inflammation, dysregulated immune response and critical multiple organ damage. Moreover, SOFA, qSOFA, APACHE II and SIRS scores appeared to be higher in COVID-19 patients with ARDS as well as non-survivors. These findings provided supporting evidence that COVID-19 patients with ARDS were associated with higher risk of worse clinical outcomes.

Multivariable logistic regression models were performed to explore risk factors related to ARDS development and death in COVID-19 patients. In terms of inflammatory-related indexes, in addition to previous reported risk factors such as neutrophils, IL-6 and CRP, we found TNF-α was a novel risk factor of ARDS development and death in COVID-19 patients. Cytokine storm has been reported to mediate extensive lung inflammation and ultimately induce ARDS in COVID-19 patients through severe systemic secretion of pro-inflammatory cytokines.$^{17,18}$ IL-6 induces various pro-inflammatory cytokines and chemokines through the regulation of STAT3 and activation of the NF-κB pathway, which ultimately causes pneumocyte and endothelial injury, vascular leakage and alveolar edema in cytokine storm.$^{19-21}$ During pulmonary infections in COVID-19 patients, intracellular IL-6 acts in concert with CXCL1 and CXCL2 to recruit polymorphonuclear leukocytes to the lung, resulting in killing pathogens but generating fibrosis.$^{22}$ TNF-α, a potential novel risk factor for the development of ARDS identified here, has been reported to mediate airway hyper-responsiveness through the induction of M2 muscarinic receptor dysfunction.$^{23}$ In addition, TNF-α not only promotes the apoptosis of both lung epithelial cells and endothelial cells but also inhibits the generation of germinal center B cells by suppressing T cell helper functions.$^{24,25}$ An overproduction of TNF-α and IL-6 indicated the exuberant inflammatory responses during course of SARS-COV-2 infection. Collectively, these findings may partly account for the influence of pro-inflammatory cytokines on the high risk of ARDS development and death in COVID-19.

Furthermore, we found that decreased immune cell subsets including T cells, B cells and NK cells, were correlated with the development risk of ARDS among COVID-19 patients and death risk among patients who developed ARDS. Notably, CD8$^{+}$ T cells and CD3$^{-}$CD19$^{+}$ B cells were identified as novel risk factors. The dysregulated cellular immune responses by decreased lymphocytes are thought to be associated with severity and mortality in COVID-19 patients.$^{26}$ CD8$^{+}$ T cells play a critical role in mediating viral clearance after acute respiratory infections of respiratory syncytial virus, influenza A virus, and human metapneumovirus.$^{27,28}$ In addition, CD8$^{+}$ T cells are reported to suppress inflammatory immune response by secreting immunosuppressive cytokines and cytotoxic enzymes, and the decreased level of CD8$^{+}$ T cells associated with the dysfunction of immune response and severe complications.$^{29}$ CD3$^{-}$CD19$^{+}$ B cells inhibit proinflammatory cytokines and support regulatory T cells differentiation by secreting anti-inflammatory cytokine IL-10.$^{30}$ Besides, CD3$^{-}$CD19$^{+}$ B cells act as a booster to the maintenance of immune homeostasis, which are associated with the poor clinical outcomes in patients with autoimmune diseases and viral infectious disease.$^{31-33}$

In addition to elevated inflammatory-related indexes and decreased immune cell subsets, we found abnormal multiple-organ damage biomarkers were another risk factors for development of ARDS and progression from ARDS to death in COVID-19 patients. Previously reported risk factors of COVID-19, such as ALT, AST, hs-cTnI, NT-proBNP, eGFR, D-Dimer and FDP were also confirmed in our study. Furthermore, we identified novel risk factors including CK-MB and ALB. The systemic inflammatory response and immune system disorders during disease progression in patients with COVID-19 result in the high incidence of organ failure symptoms and dysregulated tissue damage biomarkers.$^{34}$ Additionally, respiratory dysfunction and hypoxemia in patients with COVID-19 and ARDS caused damage to myocardial cells through the regulation of type 1 and type 2 T helper cells.$^{35}$ Moreover, The high serum levels of CK-MB suggested myocardial damage in early-stage which were correlated with the severity and case fatality rate of COVID-19.$^{36,37}$ ALB was reported to selectively suppress the expression of pro-inflammatory TNF-α by inhibiting the activation of NF-κB pathway.$^{38}$ Additionally, the decreased levels of ALB contribute to inflammatory response and oxidative stress injury through the upregulating the levels of glutathione, which partly accounted for disease severity in MERS patients.$^{38,39}$ However, it remains insufficient to explore the association between the multiple-organ damage and the pathogenesis of development of ARDS.
Previous researches have reported that SOFA, qSOFA, APACHE II, and SIRS scoring systems show good prediction accuracy for evaluating septic shock, multi-organ failure and ICU mortality.\textsuperscript{7,8,10–12,40,41} Here, we confirmed that those with higher SOFA, qSOFA, APACHE II or SIRS scores were more likely to develop ARDS and progress to death in COVID-19 patients. Moreover, we found that elevated inflammatory-related indexes, decreased immune cell subsets and abnormal multiple-organ damage biomarkers were associated with ARDS development and progression from ARDS to death in COVID-19 patients. In addition, the patients with increased levels of the biomarkers were more likely to develop complications such as heart failure, acute cardiac, kidney, liver injury and DIC. Therefore, the combined model integrating risk factors and scores showed the best predictive capacities of both development of ARDS and progression from ARDS to death in COVID-19 patients.

It is critical to recommend standardized and effective treatment protocols for SARS-COV-2 infection worldwide to improve poor clinical outcomes. Consistent with other studies, antibiotics and antivirals were widely used in COVID-19 treatment.\textsuperscript{13,42} Notably, COVID-19 patients with ARDS received more supportive therapy, such as ventilation treatments and glucocorticoid therapy. Preliminary evidence suggested the standard supportive care for ARDS patients was a protective ventilatory strategy, which might improve prognoses of patients with ARDS.\textsuperscript{43,44} Additionally, recent studies showed that corticosteroids could be an effective treatment. The administration of dexamethasone and methylprednisolone could decrease duration of mechanical ventilation and reduce the death risk of patients with COVID-19 who develop ARDS.\textsuperscript{45,46} In view of the excessive inflammation, dysregulated immune response and multiple organ damage in COVID-19 patients with ARDS, the current management of COVID-19 should be focused on inflammatory immune response, treatment of complications and supportive care, especially oxygen support.

Based on our study, several management strategies are warranted for COVID-19 patients with ARDS. First, inflammatory-related indexes and organ damage indexes should be monitored at different stages to prevent the development of ARDS in COVID-19 patients. Second, early application of systemic immune modulators such as intravenous immunoglobulin should be considered to reduce aberrant immune responses at the early stage of ARDS, which is helpful to prevent the progression of ARDS.\textsuperscript{47} Third, Supportive therapy such as ventilation treatment is also critical for COVID-19 patients with ARDS.

Our study has several limitations. First, this was a retrospective cohort study and not all laboratory tests were done in all patients. The missing data might affect the interpretation of the results. Second, the potential mechanisms of multiple organ damage and ARDS development and progression to death need to be further investigated and confirmed. Third, our study was performed in single-center hospital, which need be further confirmed in multi-center studies in the future. Finally, given that age and comorbidities, such as diabetes and hypertension, have been reported as the common risk factors of COVID-19 with ARDS, these factors were statistically matched between patients with ARDS and those without ARDS and were not included in this study.

**Conclusion**

In summary, we found higher SOFA, qSOFA, APACHE II and SIRS scores, elevated inflammatory-indexes, decreased immune cell subsets and abnormal multiple-organ damage biomarkers related to higher death risk of COVID-19 with ARDS. Furthermore, we integrated aforementioned scores and risk factors to establish a comprehensive risk prediction model for COVID-19 patients with ARDS, showing a good prediction capacity and helpful to establish protective measures for ARDS development and death.

**Abbreviations**

COVID-19, Corona virus disease 2019; SARS-COV-2, severe acute respiratory syndrome coronavirus 2; ARDS, acute respiratory distress syndrome; RT-PCR, Real-time reverse transcriptase polymerase chain reaction; SOFA, Sequential organ failure assessment; qSOFA, quick SOFA; APACHE II, The acute physiology and chronic health evaluation II; SIRS, The systemic inflammatory response syndrome; hs-CRP, High-sensitivity C-reactive protein; hs-cTnI, Hypersensitive cardiac troponin I; MERS, Middle East Respiratory Syndrome;

**Declarations**

**Ethics approval and consent to participate**
This research was approved by the Ethics Committee of Tongji Hospital Tongji Medical College, HUST. Individual informed consent was waived by the ethics committee listed above because this study used currently existing sample collected during course of routine medical care and did not pose any additional risks to the patients.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests

**Funding**

This work is supported by the China National Natural Science Foundation (No. 81974400). The funding had no role in in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Authors' contributions**

JQ, JT, and ZW were the overall principal investigators in this study who conceived the study and obtained financial support, were responsible for the study design, and supervised the entire study. ZY, TD, YW, SN, QL and CL recruited participants. JW, LW, MJ, ZL, JX, and YL drafted the paper. LW, MJ, and ZL completed the statistical analyses. JX and YL completed data analysis, interpreted the results. JQ, JT and ZW reviewed the manuscript. All authors participated in interpretation data, manuscript writing, and review of the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

We acknowledge all patients and their families involved in the study and all health-care workers who are fighting a campaign against COVID-19.

**References**

1. World Health Organization. Coronavirus disease (COVID-19) outbreak situation. Available at: [https://www.who.int/emergencies/diseases/novel-coronavirus-2019](https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Accessed 18 June 2020
2. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020; 21(3): 335-7.
3. Mehta V, Goel S, Kabarriti R, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. *Cancer Discov* 2020. Available from: [https://doi.org/10.1158/2159-8290.cd-20-0516](https://doi.org/10.1158/2159-8290.cd-20-0516)
4. The Lancet H. COVID-19 coagulopathy: an evolving story. *Lancet Haematol* 2020; 7(6): e425.
5. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; 8(4): 420-2.
6. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020; 368: m1295.
7. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* 1992; **20**(6): 864-74.

8. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med* 1985; **13**(10): 818-29.

9. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020. Available from: https://doi.org/10.1001/jama.2020.1585

10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**(10229): 1054-62.

11. Fernando SM, Reardon PM, Rochwerg B, et al. Sepsis-3 Septic Shock Criteria and Associated Mortality Among Infected Hospitalized Patients Assessed by a Rapid Response Team. *Chest* 2018; **154**(2): 309-16.

12. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. *Chest* 2018; **154**(2): 309-16.

13. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020.

14. Goh KJ, Choong MC, Cheong EH, et al. Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from COVID-19 Infection. *Ann Acad Med Singapore* 2020; **49**(3): 108-118.

15. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020: World Health Organization, 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-chi.pdf

16. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 2012; **307**(23): 2526-33.

17. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**(10229): 1033-4.

18. Vaninov N. In the eye of the COVID-19 cytokine storm. *Nat Rev Immunol* 2020; **20**(5): 277.

19. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J Antimicrob Agents* 2020; **55**(5): 105954.

20. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020; **130**(5): 2620-9.

21. Hirano T, Murakami M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. *Immunity* 2020; **52**(5): 731-3.

22. Messina G, Polito R, Monda V, et al. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work. *Int J Mol Sci* 2020; **21**(9).

23. Nie Z, Scott GD, Weis PD, Itakura A, Fryer AD, Jacoby DB. Role of TNF-alpha in virus-induced airway hyperresponsiveness and neuronal M2 muscarinic receptor dysfunction. *Br J Pharmacol* 2011; **164**(2b): 444-52.

24. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. *Am J Emerg Med* 2008; **26**(6): 711-5.

25. Popescu M, Cabrera-Martinez B, Winslow GM. TNF-alpha Contributes to Lymphoid Tissue Disorganization and Germinal Center B Cell Suppression during Intracellular Bacterial Infection. *J Immunol* 2019; **203**(9): 2415-24.

26. Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. *Lancet Respir Med* 2020; **8**(4): e24.

27. Wells MA, Ennis FA, Albrecht P. Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia. *J Immunol* 1981; **126**(3): 1042-6.

28. Cannon MJ, Stott EJ, Taylor G, Askonas BA. Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. *Immunology* 1987; **62**(1): 133-8.

29. Petrelli A, van Wijk F. CD8(+) T cells in human autoimmune arthritis: the unusual suspects. *Nat Rev Rheumatol* 2016; **12**(7): 421-8.

30. Mauri C, Bosma A. Immune regulatory function of B cells. *Annu Rev Immunol* 2012; **30**: 221-41.
31. Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. *J Clin Invest* 2017; **127**(3): 772-9.
32. Fillatreau S. Regulatory roles of B cells in infectious diseases. *Clin Exp Rheumatol* 2016; **34**(4 Suppl 98): 1-5.
33. Dai YC, Zhong J, Xu JF. Regulatory B cells in infectious disease (Review). *Mol Med Rep* 2017; **16**(1): 3-10.
34. Cao X. COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol* 2020; **20**(5): 269-70.
35. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol* 2020; **17**(5): 259-60.
36. Gerhardt W, Ljungdahl L, Herbert AK. Troponin-T and CK MB (mass) in early diagnosis of ischemic myocardial injury. The Helsingborg Study, 1992. *Clin Biochem* 1993; **26**(4): 231-40.
37. Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. *J Med Virol* 2020; **92**(7): 819-23.
38. Spinella R, Sawhney R, Jalan R. Albumin in chronic liver disease: structure, functions and therapeutic implications. *Hepatol Int* 2016; **10**(1): 124-32.
39. Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. *Int J Infect Dis* 2014; **29**: 301-6.
40. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; **315**(8): 801-10.
41. Rainth EP, Udy AA, Bailey M, et al. Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit. *JAMA* 2017; **317**(3): 290-300.
42. Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. *Lancet Oncol* 2020. Available from: https://doi.org/10.1016/s1470-2045(20)30309-0
43. Brower RG, Ware LB, Berthiaume Y, Matthay MA. Treatment of ARDS. *Chest* 2001; **120**(4): 1347-67.
44. Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. *JAMA* 2018; **319**(7): 698-710.
45. Magro G. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc. *Cytokine X* 2020: 100029. Available from: https://doi.org/10.1016/j.cytox.2020.100029
46. Gautier-Vargas G, Baldacini C, Benotmane I, et al. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab. *Kidney Int* 2020. Available from: https://doi.org/10.1016/j.kint.2020.05.022
47. Lee KY. Pneumonia, Acute Respiratory Distress Syndrome, and Early Immune-Modulator Therapy. *Int J Mol Sci* 2017; **18**(2).

Figures
Figure 1

Comprehensive prediction models for ARDS development and progression from ARDS to death in patients with COVID-19 a. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were employed to assess the predictive accuracy of models evaluating the risk of ARDS development for COVID-19 patients with SOFA, qSOFA, APACHE II and SIRS scores, inflammatory-related indexes, immune cell subsets, organ damage indexes, and combined group integrating abovementioned these factors. The multivariate logistic regression model analysis was used to establish a risk model. The stepwise regression was used for the prediction selection for the model. ROC curves and AUCs (95%CIs) values were generated to assess prognostic accuracy for each model. A two-sided $P$ value < 0.05 was considered statistically significant. b. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were employed to assess the predictive accuracy of models evaluating the death risk of ARDS patients with SOFA, qSOFA, APACHE II and SIRS scores, inflammatory-related indexes, immune cell subsets, organ damage indexes, and combined group integrating abovementioned these factors. The multivariate logistic regression model analysis was used to establish a risk model. The stepwise regression was used for the prediction selection for the model. ROC curves and AUCs (95%CIs) values were generated to assess prognostic accuracy for each model. A two-sided $P$ value < 0.05 was considered statistically significant.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile3.docx
- Additionalfile2.docx
- Additionalfile1.docx